JP2013538856A - 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 - Google Patents

単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 Download PDF

Info

Publication number
JP2013538856A
JP2013538856A JP2013531769A JP2013531769A JP2013538856A JP 2013538856 A JP2013538856 A JP 2013538856A JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013538856 A JP2013538856 A JP 2013538856A
Authority
JP
Japan
Prior art keywords
interferon
subject
pegylated
cancer
pegylated interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013531769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538856A5 (enExample
Inventor
ピー．バケル ダルレン
ビー．ジェイ．ケイ．ジョセプフ イングリド
ワング クインズホング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2013538856A publication Critical patent/JP2013538856A/ja
Publication of JP2013538856A5 publication Critical patent/JP2013538856A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013531769A 2010-10-01 2011-09-28 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 Pending JP2013538856A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38900910P 2010-10-01 2010-10-01
US61/389,009 2010-10-01
PCT/US2011/053681 WO2012044684A2 (en) 2010-10-01 2011-09-28 Interferon-beta for use as monotherapy or in combination with other cancer therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016181104A Division JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Publications (2)

Publication Number Publication Date
JP2013538856A true JP2013538856A (ja) 2013-10-17
JP2013538856A5 JP2013538856A5 (enExample) 2014-11-13

Family

ID=45890011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013531769A Pending JP2013538856A (ja) 2010-10-01 2011-09-28 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
JP2016181104A Pending JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016181104A Pending JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Country Status (9)

Country Link
US (2) US20120082647A1 (enExample)
EP (1) EP2621516B1 (enExample)
JP (2) JP2013538856A (enExample)
AU (2) AU2011308906B2 (enExample)
CA (1) CA2813304A1 (enExample)
ES (1) ES2587837T3 (enExample)
MX (1) MX2013003599A (enExample)
NZ (2) NZ705124A (enExample)
WO (1) WO2012044684A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017536353A (ja) * 2014-11-19 2017-12-07 国防医学院Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー
JP2022549742A (ja) * 2019-09-30 2022-11-28 シャンハイ インスティテュート オブ バイオロジカル プロダクツ カンパニー，リミテッド 腫瘍の相乗的阻害におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の応用
JP2022549741A (ja) * 2019-09-30 2022-11-28 シャンハイ インスティテュート オブ バイオロジカル プロダクツ カンパニー，リミテッド 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US20150366944A1 (en) 2013-02-20 2015-12-24 Yeda Research And Development Co. Ltd. Interferon treatment targeting mutant p53 expressing cells
WO2014130811A1 (en) * 2013-02-22 2014-08-28 Biogen Idec Ma Inc Interferon beta formulation
CN106132983B (zh) 2014-04-04 2021-03-26 阿雷斯贸易股份有限公司 新型IFN-β蛋白类似物
KR102666000B1 (ko) 2016-07-29 2024-05-14 서울대학교 산학협력단 cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520323A (ja) * 2002-12-26 2006-09-07 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2009036082A2 (en) * 2007-09-12 2009-03-19 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
NZ261250A (en) 1993-01-06 1997-08-22 Kinerton Ltd Ionic conjugates of polypeptides
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AR058505A1 (es) * 2005-11-04 2008-02-06 Wyeth Corp Combinaciones antineoplasicas de temsirolimus y malato de sunitinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520323A (ja) * 2002-12-26 2006-09-07 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2009036082A2 (en) * 2007-09-12 2009-03-19 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015031767; Ｂａｋｅｒ，　Ｄ．　Ｐ．　ｅｔ　ａｌ．: 'Ｎ-ｔｅｒｍｉｎａｌｌｙ　ＰＥＧｙｌａｔｅｄ　ｈｕｍａｎ　ｉｎｔｅｒｆｅｒｏｎ-ｂｅｔａ-１ａ　ｗｉｔｈ　ｉｍｐｒｏｖｅｄ　ｐｈａｒｍａｃｏｋｉｎｅｔｉｃ　ｐｒｏｐｅｒｔｉｅｓ　ａｎｄ　ｉｎ　ｖｉｖｏ' Ｂｉｏｃｏｎｊｕｇ．　Ｃｈｅｍ． １７巻１号, 2006, ｐｐ．　１７９-１８８ *
JPN7015002177; 川野紀子ら，，: 'ＩＦＮ-beta併用多剤化学療法（ＤＡＣ-Ｔａｍ療法）が奏功した直腸肛門部悪性黒色腫の１例．' 日本消化器病学会雑誌 １０５巻１１号, 2008, ｐｐ．　１６２７-１６３３ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017536353A (ja) * 2014-11-19 2017-12-07 国防医学院Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー
JP2022549742A (ja) * 2019-09-30 2022-11-28 シャンハイ インスティテュート オブ バイオロジカル プロダクツ カンパニー，リミテッド 腫瘍の相乗的阻害におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の応用
JP2022549741A (ja) * 2019-09-30 2022-11-28 シャンハイ インスティテュート オブ バイオロジカル プロダクツ カンパニー，リミテッド 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用
JP7412577B2 (ja) 2019-09-30 2024-01-12 シャンハイ インスティテュート オブ バイオロジカル プロダクツ カンパニー，リミテッド 腫瘍の相乗的阻害におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の応用
JP7412576B2 (ja) 2019-09-30 2024-01-12 シャンハイ インスティテュート オブ バイオロジカル プロダクツ カンパニー，リミテッド 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用

Also Published As

Publication number Publication date
MX2013003599A (es) 2013-07-29
NZ705124A (en) 2016-08-26
JP2017025086A (ja) 2017-02-02
US20120082647A1 (en) 2012-04-05
WO2012044684A3 (en) 2012-06-28
EP2621516A4 (en) 2014-04-09
EP2621516A2 (en) 2013-08-07
ES2587837T3 (es) 2016-10-27
NZ608630A (en) 2015-03-27
US20160228513A1 (en) 2016-08-11
CA2813304A1 (en) 2012-04-05
AU2011308906B2 (en) 2016-06-16
EP2621516B1 (en) 2016-06-22
AU2016228234A1 (en) 2016-10-06
WO2012044684A2 (en) 2012-04-05
AU2011308906A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
JP2017025086A (ja) 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
EP3972690A1 (en) Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4596046A2 (en) Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2024520202A (ja) Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患を治療する方法
KR20090016707A (ko) Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
AU2020319899A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP2009543810A (ja) インターロイキン２１およびチロシンキナーゼ阻害剤の併用治療の方法
Minami et al. Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer
US7842292B2 (en) Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
JP2009539916A (ja) ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用
WO2022109302A9 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US12233107B2 (en) GHRH or analogues thereof for use in treatment of hepatic disease
JP2025508846A (ja) 疾患の治療のための経口オクトレオチド
CN119947713A (zh) 用于精准癌症治疗的组合物及精准癌症治疗方法
RU2597795C2 (ru) Ингибитор скопления жидкости в полостях организма
CN107441096A (zh) Rs 504393在制备治疗吉西他滨化疗中断膀胱癌的药物中的应用
WO2025096687A1 (en) Methods of treating pancreatic ductal adenocarcinoma with a toll-like receptor 9 agonist
WO2025113598A9 (zh) 稳定的混合抗体的药物组合物
AU2024287304A1 (en) Compositions and methods for treating multiple sclerosis
JP2004143113A (ja) インターフェロン製剤及びその投与システム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160517